CLAIMS

I/we claim:

1. A method of treating papulopustular rosacea in a subject in need thereof, comprising topically administering to a skin area affected by the papulopustular rosacea a therapeutically effective amount of a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein the subject has moderate to severe papulopustular rosacea before the treatment.

3. The method of claim 1, wherein the subject has 15 or more inflammatory lesions of the papulopustular rosacea before the treatment.

4. The method of claim 1, wherein as early as 2 weeks after the initial administration of the pharmaceutical composition, a significant reduction in inflammatory lesion count is observed.

5. The method of claim 1, wherein the pharmaceutical composition is administered once daily to the skin area.

6. The method of claim 5, wherein the pharmaceutical composition comprises about 0.5% to 1.5% by weight ivermectin.

7. The method of claim 6, wherein the pharmaceutical composition comprises about 1% by weight ivermectin.

8. The method of claim 6, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.

9. The method of claim 1, wherein once daily topically administering to the subject the pharmaceutical composition results in more reduction in inflammatory lesion count in the

subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

10. The method of claim 1, wherein once daily topically administering to the subject the pharmaceutical composition results in longer relapse-free time of the papulopustular rosacea in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

11. A method of treating inflammatory lesions of papulopustular rosacea in a subject in need thereof, comprising topically administering, once daily, to a skin area affected by the inflammatory lesions of papulopustular rosacea a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier.

12. The method of claim 11, wherein the subject has moderate to severe papulopustular rosacea before the treatment.

13. The method of claim 11, wherein the subject has 15 or more of the inflammatory lesions before the treatment.

14. The method of claim 11, wherein as early as 2 weeks after the initial administration of the pharmaceutical composition, a significant reduction in inflammatory lesion count is observed.

15. The method of claim 11, wherein the pharmaceutical composition is administered once daily to the skin area.

16. The method of claim 15, wherein the pharmaceutical composition comprises about 0.5% to 1.5% by weight ivermectin.

17. The method of claim 16, wherein the pharmaceutical composition comprises about 1% by weight ivermectin.

18. The method of claim 16, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium

silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.

19. The method of claim 11, wherein once daily topically administering to the subject the pharmaceutical composition results in more reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

20. The method of claim 11, wherein once daily topically administering to the subject the pharmaceutical composition results in longer relapse-free time of the inflammatory lesions in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

CLAIMS

1. Use of a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of papulopustular rosacea in a subject in need thereof, wherein the medicament is to be topically administered, once daily, to a skin area affected by the papulopustular rosacea, and wherein the treatment results in a significant reduction in inflammatory lesion count in the subject as early as two weeks after the initial administration of the medicament.

2. The use of claim 1, wherein the subject has moderate to severe papulopustular rosacea before the treatment.

3. The use of claim 1, wherein the subject has 15 or more inflammatory lesions of the papulopustular rosacea before the treatment.

4. The use of claim 1, wherein the pharmaceutical composition comprises about 0.5% to 1.5% by weight ivermectin.

5. The use of claim 4, wherein the pharmaceutical composition comprises about 1% by weight ivermectin.

6. The use of claim 4, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.

7. The use of claim 1, wherein the treatment results in a greater reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

8. The use of claim 1, wherein the treatment results in longer relapse-free time of the papulopustular rosacea in the subject in comparison to that achieved by topically administering

to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

9. Use of a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of inflammatory lesions of papulopustular rosacea in a subject in need thereof, wherein the medicament is to be topically administered, once daily, to a skin area affected by the papulopustular rosacea, and wherein the treatment results in a significant reduction in inflammatory lesion count in the subject as early as two weeks after the initial administration of the medicament.

10. The use of claim 9, wherein the subject has moderate to severe papulopustular rosacea before the treatment.

11. The use of claim 9, wherein the subject has 15 or more of the inflammatory lesions before the treatment.

12. The use of claim 9, wherein the pharmaceutical composition comprises about 0.5% to 1.5% by weight ivermectin.

13. The use of claim 12, wherein the pharmaceutical composition comprises about 1% by weight ivermectin.

14. The use of claim 12, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.

15. The use of claim 9, wherein the treatment results in a greater reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

16. The use of claim 9, wherein the treatment results in longer relapse-free time of the inflammatory lesions in the subject in comparison to that achieved by topically administering to

the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.